Pmh49 - Launching Long Acting Products to Treat Opioid Use Disorder: Are Payers Willing to Pay Premium Price?

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1684
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Vaccines to Treat Opioid Use Disorders and to Reduce Opioid Overdoses

Neuropsychopharmacology
PsychiatryMental HealthPharmacology
2018English

Willingness to Pay Price Premium for Smartphones Produced Using Renewable Energy

Sustainability
DevelopmentManagementMonitoringEnvironmental ScienceRenewable EnergyEnergy EngineeringLawSustainabilityPlanningPolicyPower Technologythe EnvironmentGeography
2019English

How Much Are Public School Teachers Willing to Pay for Their Retirement Benefits?

2014English

Crop Insurance Scheme Among Paddy Farmers in Kedah, Malaysia: Are They Willing to Pay?

Journal of Social Sciences Research
ArtsFinanceHumanitiesEconomicsEconometricsSocial Sciences
2018English

Pengaruh Brand Loyalty, Brand Love, Brand Commitment Terhadap Willingness to Pay a Premium Price

Jurnal Manajemen Bisnis dan Kewirausahaan
2019English

Long-Acting MIC-1/GDF15 Molecules to Treat Obesity: Evidence From Mice to Monkeys

Science Translational Medicine
Medicine
2017English

A High Price to Pay

Learning Disability Practice
2000English

How Much Are Insurance Consumers Willing to Pay for Blockchain and Smart Contracts? A Contingent Valuation Study

Sustainability
DevelopmentManagementMonitoringEnvironmental ScienceRenewable EnergyEnergy EngineeringLawSustainabilityPlanningPolicyPower Technologythe EnvironmentGeography
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy